Neurotech International Ltd has released a press release.
Significant improvement in Autism patients at 12 weeks
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Story so far
Earlier from Neurotech International
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
- Further clinical benefit at 52 weeks in PANDAS/PANS patients
- Rett Syndrome Phase I/II trial shows significant benefits
- Neurotech Completes $10 Million Capital Raise
- Positive Top-Line Rett Syndrome Clinical Trial Results
Later from Neurotech International
- Phase II/III autism trial shows further benefits
- Further Significant Improvement in Rett Syndrome Patients
- Neurotech Global Partnering and Registration Strategy
- NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
- US FDA Response to Orphan Drug Request in PANDAS/PANS
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International